VANCOUVER, BC, Sept. 26, 2023 /PRNewswire/ — Wondershare Technology, a globally recognized software company, is excited to announce the release of EdrawMind V10.9.0, the latest version of their leading mind mapping and brainstorming tool. This update introduces a range of features aimed at revolutionizing the way users visualize ideas, enhancing efficiency, and fostering creativity. By harnessing cutting-edge technology, this new version seeks to cater to the diverse needs of professionals, students, and anyone looking to transform their thoughts into organized, dynamic, and visually appealing diagrams.

Integration with OpenAI: This feature enables seamless interaction with ChatGPT, integrating powerful AI capabilities into EdrawMind, thereby improving user experience through intelligent suggestions and assistance.Intelligent Document Parsing: EdrawMind can now intelligently analyze and process documents, extracting key information and assisting users in creating mind maps based on existing documents.PPT Generation: A valuable addition for users seeking to convert their mind maps into presentation slides efficiently.Inspiration Space: This dedicated space within the software encourages brainstorming and idea collation, thus streamlining the creative process.Exploration of Audio and Video: EdrawMind V 10.9.0’s new capability to handle audio and video content allows users to enrich their mind maps with multimedia elements.Versatile and Vertical Mind Map Posters: This feature provides users with myriad options for creating and customizing mind map posters, both in terms of layout and design.”In our relentless pursuit of enhancing user experiences, we are thrilled to introduce the integration of OpenAI into EdrawMind. This transformative update brings AI-driven features like intelligent file parsing and effortless PPT generation directly to our users, empowering them to achieve new levels of productivity and creativity. But our commitment doesn’t end here. We envision a future where our AI continually evolves, learns, and adapts to better serve and inspire our users on their creative journeys.” – Iris Liu, Head of Wondershare BrandingWondershare
Compatibility and Price 
Wondershare EdrawMind is compatible with Windows, Mac, Android and iOS and pricing starts at $39 for a six-month subscription. For free trials and downloads, please visit our official website or follow us on YouTube, Facebook, Twitter, and Instagram to learn more about EdrawMind.  Additionally, with an EdrawMind membership, you can enjoy cross-platform benefits across all EdrawMind platforms.
About Wondershare
Wondershare is globally recognized as a software company that is committed to delivering innovative solutions for personal and professional use. As a leader in creativity and productivity products, Wondershare has received prestigious awards from organizations such as The Shorty Awards, G2, and GetApp. At Wondershare, the mission is to empower individuals to pursue their passions and build a more creative world. With over 100 million users across 150 countries, users can access a wide range of software solutions for video editing, PDF editing, data recovery, diagram and graphics, and more. Together, Wondershare strives to provide high-quality, user-friendly software that enables individuals and businesses to bring their creative ideas to life. 
Photo – https://mma.prnewswire.com/media/2219737/MicrosoftTeams_image__1.jpg
Logo – https://mma.prnewswire.com/media/1274391/wondershare_LOGO.jpg

View original content:https://www.prnewswire.co.uk/news-releases/edrawmind-v10-9-0-s-new-features-revolutionizing-the-way-users-visualize-ideas-301937753.html

KardiaMobile® 6L is the first smartphone-based personal electrocardiogram (ECG) to be conditionally recommended by the National Institute for Health and Care Excellence (NICE) as part of its Early Value Assessment (EVA) pilot project.1KardiaMobile 6L has been recommended for use in psychiatric services as an option to measure cardiac QT interval for adults having or about to have antipsychotic medication, subject to the generation of additional evidence.1People taking antipsychotic medication are at increased risk of severe cardiac events 1 and their life expectancy is significantly lower than the general population.2There is an unmet need for more accessible and available measurements for detecting cardiac abnormalities in psychiatric services.1MOUNTAIN VIEW, Calif., Sept. 26, 2023 /PRNewswire/ — AliveCor, the world’s leading innovator in personal electrocardiogram (ECG) technology, today announced the publication of the Early Value Assessment (EVA) by the National Institute for Health and Care Excellence (NICE) which conditionally recommends the use of KardiaMobile 6L in psychiatric services as an option to measure cardiac QT interval for adults having, or about to have, antipsychotic medication.1

There is an unmet clinical need for a more easily accessible and available measurement for detecting cardiac abnormalities in NHS psychiatric services, as antipsychotic medication can prolong the QT interval* and lead to severe cardiac events.1 Detecting cardiac abnormalities in people taking antipsychotic medication – such as prolonged QT interval – can inform choice of therapy, dosing and whether to stop therapy, and potentially avoid severe cardiac events, which are contributing to the significantly lower life expectancy of these patients, as compared to the general population. 1, 2 KardiaMobile 6L is a portable ECG recording device that provides instant detection of cardiac abnormalities and can be used to measure heart changes including cardiac QT interval.1
“Timely ECG monitoring of patients who are on antipsychotic medication can save lives. Having access to KardiaMobile 6L will mean potentially vulnerable patients can now be seen in the comfort of their homes, reducing their stress whilst ensuring that this essential monitoring is completed anywhere, at any time. It’s encouraging that NICE has recognised the need for early access to this important technology,” said Dr Mani Krishnan, Consultant Psychiatrist and Specialty Clinical Director, Tees, Esk and Wear Valleys NHS Foundation Trust.
KardiaMobile 6L has been recommended as part of NICE’s EVA pilot project, created to drive earlier access to promising healthcare innovations for use within the National Health Service in England and Wales. The first and only NICE recommended smartphone-based ECG device, KardiaMobile 6L can be used by healthcare professionals in both a hospital setting and as part of routine home visits.1 This may reduce stress and anxiety amongst psychiatric patients as the test can be completed in familiar surroundings.1 Portable ECG testing also eliminates the need for travel and the requirement for conductive gel and undressing, which can cause reluctance and distress for patients.1 KardiaMobile 6L has the potential to ensure timely ECG testing is available which could help adults having antipsychotic medication get faster access to safe and effective antipsychotic treatment.1
“We are delighted that KardiaMobile 6L has been recognised by NICE and reviewed by the Early Value Assessment pilot project. This decision is testament to the clinical importance of detecting and monitoring heart disturbances both in clinic and at home, something especially important in psychiatric services,” said Sean Warren, Business Director UK&I, AliveCor. “We have a wealth of clinical data on the use of KardiaMobile 6L in cardiology, with NICE’s EVA recommendation we will now support the collection of real-world evidence as to its effectiveness in psychiatric services. We applaud NICE and the physicians that have worked on this project for their forward-thinking approach to the use of novel health tech within the NHS, as we know it is patients that will be the ultimate beneficiaries.”
NICE’s decision was based on a systematic review of eight studies that evaluated the technical performance of KardiaMobile 6L compared with a 12-lead device.1 Conditional to NICE’s positive recommendation is that further evidence on the use of this innovative technology in psychiatric services must be generated to inform a further full technology reassessment.1
*A prolonged QT interval indicates an abnormality detected on an ECG.3 This abnormality reflects a disturbance in the conduction of electricity in the lower chamber (ventricles) of the heart.3 Multiple factors can trigger prolonged QT interval including high doses of medications such as antihistamines, decongestants, diuretics, antibiotics, and antidepressants.3
Notes to editor
NICE’s EVA recommendation for KardiaMobile 6L’s use in psychiatric services1
KardiaMobile 6L can be used in psychiatric services as an option to measure cardiac QT interval for adults having or about to have antipsychotic medication while more evidence is generated only if:
A repeat QT interval measurement using a 12-lead electrocardiogram (ECG) device is offered to:Women with a corrected QT interval (QTc) longer than 470 millisecondsMen, trans people having hormone treatment, and intersex people who have QTc longer than 440 millisecondsPeople who have a follow-up ECG with more than a 50 millisecond increase in QTcFor trans people not having hormone treatment, use the QTc threshold for their sex registered at birthTraining for healthcare professionals on recording an ECG, and measuring and interpreting QT interval is providedPeople are offered information about why this testing is done and why testing may be repeated using a 12-lead device after it has been measured using KardiaMobile 6LAdditional evidence required by NICE on KardiaMobile 6L in the use of psychiatric services1
NICE has requested that additional evidence is generated on:
The accuracy of KardiaMobile 6L to measure QT interval in adults having or about to have antipsychotic medicationsHow the test result affects clinical decision makingHow long the testing takes, who interprets the results and how often the test is repeated using a 12-lead devicePatient preferencesHow long it takes before antipsychotic medication is startedHow many adults who need an ECG to measure QT interval have oneHow common prolonged QT is in adults having antipsychotic medicationAbout AliveCor
AliveCor, Inc. is transforming cardiological care using deep learning. The FDA-cleared KardiaMobile device is the most clinically-validated personal ECG solution in the world. KardiaMobile 6L provides instant detection of Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with Supraventricular Ectopy, Sinus Rhythm with Premature Ventricular Contractions, Sinus Rhythm with Wide QRS, and Normal Sinus Rhythm in an ECG. Kardia is the first AI-enabled platform to aid patients and clinicians in the efficient detection of atrial fibrillation, the most common arrhythmia and one associated with a highly-elevated risk of stroke. AliveCor’s enterprise platform allows third-party providers to manage their patients’ and customers’ heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies. AliveCor protects its customers with stringent data security and compliance practices, achieving ISO 27001 Certification, SOC 2 Type 2 Certification and HIPAA compliance attestation. AliveCor is a privately-held company headquartered in Mountain View, Calif. “Consumer” or “Personal” ECGs are ECG devices available for direct sale to consumers. For more information, visit alivecor.com.
For further information please contact:
Ruder FinnAnnabelle RedfernT: +44 (0) 79509 [email protected] 
AliveCorFor media enquiries:Chris [email protected] 
For business enquiries:Sean [email protected]
References
1   NICE. Health Technology Evaluation: KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication (HTE10). 2023. Available at: https://www.nice.org.uk/guidance/hte10. Last accessed: September 2023.
2 NICE. Diagnostics Assessment Programme: KardiaMobile 6L for measuring QT interval in people having antipsychotic medication. Final scope. 2022. Available at: https://www.nice.org.uk/guidance/gid-hte10026/documents/final-scope. Last accessed: September 2023.
3 NHS Long QT Syndrome. 2017. Available at: https://www.nhs.uk/conditions/long-qt-syndrome. Last accessed: September 2023.

View original content:https://www.prnewswire.co.uk/news-releases/alivecors-kardiamobile-6l-becomes-first-personal-ecg-device-recommended-for-use-in-psychiatric-services-in-england-and-wales-301938573.html

Achieving EV adoption targets will require massive growth in battery manufacturing and raw material supply
LONDON, Sept. 26, 2023 /PRNewswire/ — With aggressive government decarbonization targets and OEM electrification strategies, Electric Vehicle (EV) production will majorly increase this decade. This will require a corresponding growth in EV battery output. New research from global technology intelligence firm ABI Research finds that global EV battery output production will increase nearly six times to 2,585 GWh by 2030.

“Battery cost and production volume are the key barriers to adoption for EVs. The most important technologies are, therefore, those that make batteries cheaper or easier to manufacture at scale. Revolutionary technologies such as solid-state batteries promise improved ranges and reduced charging times, generating much media attention, but are too expensive and difficult to manufacture. Battery developments this decade will focus on evolutionary improvements on current lithium-ion batteries,” says Dylan Khoo, Electric Vehicles Industry Analyst at ABI Research.
The most advanced lithium-ion batteries currently available can achieve 1,000 km of range or charge in under 20 minutes. Further improvements will be made through technologies like the fully silicon anodes developed by companies such as Sila, expected to be delivered as soon as 2025. Solid-state batteries are unlikely to significantly impact this decade because their adoption would require changes in cell design and manufacturing, unlike improvements on existing lithium-ion battery technology.
This EV battery boom will put pressure on supplies of raw materials. From 2022 to 2030, there will be a 5.3x increase in demand for lithium and a 3.2x increase in demand for cobalt for EV batteries. Reducing the consumption of these critical minerals is an essential goal for battery manufacturers, particularly cobalt, due to its volatile supply and unethical practices involved in its mining. The average cobalt content of EV batteries will decrease by 44% by 2030. Improved pack assembly techniques, such as cell-to-pack (C2P) technology, will increase the overall energy density of cobalt-free Lithium Iron Phosphate (LFP), allowing them to be used in more applications. Cobalt content can also be reduced by increasing overall energy density with high-nickel Nickel Manganese Cobalt (NMC) cathodes.
“There are EVs with long ranges and EVs that can charge quickly, but there are no EVs that cost the same as their fossil fuel counterparts. Evolutionary improvements over current lithium-ion battery technology will be essential to reduce the cost of EVs and achieve industrywide electrification targets,” concludes Khoo.
These findings are from ABI Research’s Next-Generation Electric Vehicle Batteries application analysis report. This report is part of the company’s Electric Vehicles research service, which includes research, data, and ABI Insights. Based on extensive primary interviews, Application Analysis reports present an in-depth analysis of key market trends and factors for a specific technology.
About ABI Research
ABI Research is a global technology intelligence firm delivering actionable research and strategic guidance to technology leaders, innovators, and decision makers around the world. Our research focuses on the transformative technologies that are dramatically reshaping industries, economies, and workforces today.
ABI Research是一家国际科技情报公司，为全球科技领袖、创新人士和决策者提供实用的市场研究和战略性指导。我们密切关注一切为各行各业、全球经济和劳动市场带来颠覆性变革的创新与技术。
For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.
Contact Info: 
Global Deborah Petrara Tel: +1.516.624.2558 [email protected]  
Logo – https://mma.prnewswire.com/media/1471031/ABI_Research_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/evolutionary-lithium-ion-battery-improvements-will-drive-a-sixfold-increase-of-global-ev-battery-output-production-to-over-2-500-gwh-by-2030–301938216.html